Back to top
more

Haemonetics (HAE)

(Real Time Quote from BATS)

$84.85 USD

84.85
53,401

+0.77 (0.92%)

Updated Jun 3, 2024 11:08 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Tirthankar Chakraborty headshot

Buy These 4 Efficient Stocks for Impressive Returns

We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns

    Why Should You Add Haemonetics (HAE) to Your Portfolio Now?

    Market seems to be upbeat about Haemonetics' (HAE) newly-launched platform, NexSys Plasma Collection System (PCS).

      Cerus (CERS) Looks Good: Stock Adds 9.5% in Session

      Shares of Cerus (CERS) rose 9.5% on Friday

        Zacks.com highlights: Copart, Haemonetics, Surmodics, Alarm.com Holdings and ConocoPhillips

        Zacks.com highlights: Copart, Haemonetics, Surmodics, Alarm.com Holdings and ConocoPhillips

          Tirthankar Chakraborty headshot

          5 Top-Ranked Efficient Stocks to Boost Your Portfolio

          A company with a favorable efficiency level will provide impressive returns irrespective of market conditions

            Haemonetics (HAE) Up 4.2% Since Earnings Report: Can It Continue?

            Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

              Haemonetics (HAE) Hits a 52-Week High: What's Driving It?

              Haemonetics (HAE) upbeat on integration of NexSys PCS device. A raised EPS guidance buoys optimism.

                Medical Device Industry Outlook - February 2018

                Amid the concerns related to the tax reform, Congress' postponement of the medical device tax for another two years came as a huge relief to industry participants and investors.

                  Here's Why You Must Add Haemonetics (HAE) to Your Portfolio

                  Haemonetics (HAE) delivers strong plasma revenues, driven by a robust performance in disposables and software in the United States. Also, the market seems upbeat about this new PCS platform.

                    Zacks.com featured highlights include: Lululemon, Haemonetics, NVR, YY and ConocoPhillips

                    Zacks.com featured highlights include: Lululemon, Haemonetics, NVR, YY and ConocoPhillips

                      International Business Aids NuVasive, Pricing Woe Remains

                      NuVasive (NUVA) plans to merge its U.S. Commercial and International sales functions into a global commercial organization. Also, several recent FDA approvals are encouraging.

                        Tirthankar Chakraborty headshot

                        5 Top Efficient Stocks to Add to Your Portfolio

                        Companies with favorable efficiency levels are likely to be on investors' radar irrespective of market conditions as price performance is believed to be positively correlated with efficiency

                          BD (BDX) Launches PAXgene in Europe for Advanced DNA Testing

                          Becton, Dickinson and Company's (BDX) PAXgene ccfDNA gets a commercial launch in Europe and enables improved DNA testing in comparison to standard EDTA tubes.

                            NuVasive's SpineTRACK Registry Gains New CMS Designation

                            NuVasive's (NUVA) receipt of the QCDR designation for its SpineTRACK buoys optimism for the stock. This achievement might add value to cushion its efforts to provide systems-based spine solutions.

                              Luminex (LMNX) Banks on Solid Product Line, Competition Rife

                              Luminex's (LMNX) extensive product line and rising revenues raise optimism. However, a challenging reimbursement scenario is likely to mar prospects.

                                Abiomed's Extended FDA Nod for Impella Refines PCI Diagnosis

                                Abiomed (ABMD) gets second FDA PMA for its flagship Impella in a row, with a view to treating patients with High Risk PCI.

                                  Haemonetics (HAE) Banks on Plasma Franchise, Competition Rife

                                  Haemonetics' (HAE) strong end-market demand for plasma-derived biopharmaceuticals continues to drive growth.

                                    Haemonetics (HAE) Hits a 52-Week High: What's Driving It?

                                    Haemonetics (HAE) gains from promising financial results in the third quarter of fiscal 2018.

                                      Is Surprise Coming for Haemonetics (HAE) This Earnings Season?

                                      Is Surprise Coming for Haemonetics (HAE) This Earnings Season?

                                        Haemonetics Banks on Hospital Business, Competition Rife

                                        For fiscal 2018, Haemonetics (HAE) expects the Hospital business to grow 7-10%.

                                          Haemonetics (HAE) at 52-Week High: What's Driving the Stock?

                                          Haemonetics (HAE) focuses on development and launch of NexSys PCS plasmapheresis system.

                                            Haemonetics (HAE) Grows on Strong Plasma, Competition Rife

                                            Despite stiff competition, Haemonetics (HAE) grows on the back of its Plasma and Haemonetics Management franchises.

                                              Haemonetics (HAE) in Focus: Stock Moves 10% Higher

                                              Haemonetics (HAE) saw its shares rise nearly 10% on the day after the company reported better-than-expected second quarter and first Half Fiscal 2018 results.

                                                Haemonetics Grows on Strong Plasma, Blood Center Sluggish

                                                Haemonetics' (HAE) encouraging growth in both Plasma and Haemonetics Management franchises keeps the market upbeat. However, slow revenue growth at the Blood Center franchise raises concern.

                                                  Haemonetics Plasma Arm Grows Strong, Blood Center Sluggish

                                                  Haemonetics (HAE) registers strong top-line growth, banking on Plasma, TEG, hemostasis management as well as a strong cash position. Blood Center drag continues.